Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  tositumomab and iodine I 131 tositumomab
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-19 of 19 for your search:
Start Over
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068321, U10CA032102, S0016, CALGB-50102, SWOG-S0016, ECOG-SWOG-S0016, NCT00006721
Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: NCI, NHLBI
Protocol IDs: 384, BMT CTN 0401, U01 HL069294-05, FHCRC-2125.00, NCT00329030
Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: 11-095, NCT01484093
hase II Study of Combined B-Cell Purging and CD34+ Enrichment of Mobilized Peripheral Blood Progenitor Cells for Autologous Hematopoietic Transplantation in Patients with Relapsed Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 14 to 70
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CWRU-CELL-1497, CP-0154-010, NCI-G98-1430
S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066917, S9911, U10CA032102, SWOG-9911, NCT00003784
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 59
Sponsor: NCI, Other
Protocol IDs: 1368.00, NCI-2009-01469, P01CA044991, FHCRC-1368.00, NCT00073918
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP-99-032, NCT00022932
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP-99-037, NCT00022945
S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000415955, S0433, U10CA032102, SWOG-S0433, NCT00107380
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2005.035, IRB # 2005-0403 and HUM 43767, NCT00135200
Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 393229/032, NCT00240565
Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: PSOC 2301, NCI-2011-01311, P30CA015704, NCT00476047
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LYM 2005-01, NCT00479167
Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 19 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LYMNHL0019, 10275, NCT00490009
Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 60 to 80
Sponsor: NCI, Other
Protocol IDs: 1366.00, CDR0000341125, FHCRC-1366.00, NCT00073931
Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 19 to 70
Sponsor: Other
Protocol IDs: 051-00, UNMC-051-00, COULTER-IND-3323, NCT00006695
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 60 and over
Sponsor: NCI, Other
Protocol IDs: 1943.00, NCI-2009-01470, P01CA044991, FHCRC-1943.00, NCT00110071
Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 100
Sponsor: NCI, Other
Protocol IDs: JHOC-J0636, CDR0000522705, NCT00416312
Start Over